TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01509469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: Ileal infusion of low dose casein (5 gram)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: Ileal infusion of high dose casein (15 gram)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ileal infusion of low dose sucrose (4.3 gram)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ileal infusion of high dose sucrose (12.9 gram)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Ileal infusion with saline (180mL in total)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Safflower oil
Description: Ileal infusion with safflower oil (6gr safflower oil in water)
Study: NCT04566653

Intervention type: DRUG
Intervention: Calcium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Calcium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Lokelma® 5 g/45mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Lokelma® 10 g/45 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Veltassa® 8,4 g/80mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Veltassa® 8,4 g/80mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Sodium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)

Intervention type: DRUG
Intervention: Sodium Polystyrene Sulphonate 15g/60 mL water
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Study: NCT01236872

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 250ml once of beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 250ml once of low-nitrate mineral water
Study: NCT03957941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyLink Pumping
Description: Viewing baby via FamilyLink while pumping

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pumping
Description: Not viewing baby via FamilyLink while pumping
Study: NCT04528615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCK In-Person Sessions
Description: This group attended eight weeks of nutrition education-focused experiential learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCK Printed Materials
Description: This group did not attend any in-person sessions and was only provided with select CCK written materials.
Study: NCT02061397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Product
Description: Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study: NCT01542632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV New Formulation
Description: TDV New Formulation subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV New Formulation
Description: TDV New Formulation subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Placebo
Description: New Formulation placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Placebo
Description: New Formulation placebo subcutaneous injection
Study: NCT03903861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose alone
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galactose alone
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose and galactose
Description: Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
Study: NCT01635387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: 150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aliskiren
Description: 150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
Study: NCT04759040

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Migraineguard
Description: 2 Capsules per day for 7 Months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Migraineguard
Description: 2 Capsules per day for 7 Months
Study: NCT00099606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
Study: NCT02913885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curodont Repair
Description: composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: fluoride inhibit the progression of white spot lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride inhibit the progression of white spot lesion
Study: NCT03123549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: Simplify Disc at two levels of the cervical spine
Study: NCT02293200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: basic life support without any feedback device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: basic life support without any feedback device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueCPR
Description: CPR with feedback device
Study: NCT04787276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E.coli Nissle 1917
Description: Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: rifaximin, oral, 500 mg BID, 1 months of treatment
Study: NCT01751269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Study: NCT00243789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day.
Study: NCT03071627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New items without spin
Description: Interpretation of news items without spin
Study: NCT03077802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique, Experienced group
Description: This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
Study: NCT03642327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Maintenance of Certification (MOC)
Description: MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Independent online training (IND)
Description: IND refers to practitioners Independently doing the online training.
Study: NCT03602742

Intervention type: DEVICE
Group type: OTHER
Intervention: EZYPRO®
Description: Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
Study: NCT04272749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assess opinons on the milk beverages
Description: Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
Study: NCT02090166

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: a blood test will be taken from each patient
Study: NCT02943590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill taken once a day
Study: NCT03677661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation program
Description: The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
Study: NCT03115021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPCS
Description: A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tPCS
Description: Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
Study: NCT02061397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Oral Product
Description: Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study: NCT03077802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique, Experienced group
Description: This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
Study: NCT03115021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tPCS
Description: Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
Study: NCT05066646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT103A
Description: CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
Study: NCT03556098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose-dependent insulinotropic peptide
Description: Infusion of GIP
Study: NCT02943590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A pill taken once a day
Study: NCT01827865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study: NCT03556098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Dependent Insulin-Releasing Hormone[3-30]
Description: Infusion of GIP antagonist GIP\[3-30\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Infusion of Saline
Study: NCT04069377

Intervention type: DEVICE
Intervention: LUCAS™ 2 Chest Compression System
Description: LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.

Intervention type: OTHER
Intervention: Manuel chest compressions by human efforts
Description: In this way chest compressions will be handled by humans themselves.
Study: NCT01994863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product
Description: Coloplast test product is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product
Description: Coloplast test product is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima
Study: NCT00203112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate with minocycline
Description: Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
Study: NCT01827865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study: NCT00203112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate with placebo
Description: Subcutaneous injection glatiramer acetate 20mg, with oral placebo
Study: NCT04355858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7390
Description: MEK1/2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Multi-target tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Multi-target tyrosine kinase inhibitor
Study: NCT01827865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study: NCT03103516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early epidural decompression group
Description: The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
Study: NCT04355858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Multi-target tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: PARP inhibitor
Study: NCT01039610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description
Study: NCT04355858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: HER1 / HER2 receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Albumin bound paclitaxel
Study: NCT03103516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed epidural decompression group
Description: The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
Study: NCT04355858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Albumin bound paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: EZH2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: EZH2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: AR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1701
Description: anti-PD-L1/TGF-βRII bifunctional fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1701
Description: anti-PD-L1/TGF-βRII bifunctional fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI
Description: aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFi
Description: Bevacizumab
Study: NCT03972319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day
Description: 4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
Study: NCT03023254

Intervention type: OTHER
Group type: OTHER
Intervention: Hydrotherapy
Description: 3-week Avène hydrotherapy